PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Robert Dreicer, MD, MS, MACP, FASCO - Unraveling the Complexities of Prostate Cancer Management: Focus on Therapeutic Decisions for Early-Stage Disease and the Implications for Later-Stage Disease
Go online to PeerView.com/XHP860 to view the entire program with slides. In this activity, experts in the management of patients with prostate cancer discuss recent advances that have rapidly expanded the therapeutic landscape, including treatments for both early-stage and advanced disease. Focusing on selection and sequencing of therapies based on patient and tumor characteristics, prior treatment history, and patient preferences, the expert panel provides an engaging MasterClass and Practicum that combines key clinical evidence and current guideline recommendations with practical guidance for personalizing application of approved and investigational therapies throughout the prostate cancer disease continuum, including nonmetastatic (M0), metastatic hormone-sensitive, and metastatic castration-resistant settings. Upon completion of this activity, participants should be better able to: Evaluate the efficacy, safety, and clinical role of approved and investigational therapies, including hormone, cytotoxic, immuno-oncology, bone-directed, and molecularly targeted therapies alone or in combination for localized, M0, and advanced prostate cancer, Assess current clinical trials evaluating agents with varying modalities alone or in combination and refer appropriate patients with prostate cancer for clinical trial enrollment, Recommend individualized treatment plans for patients with prostate cancer throughout the disease continuum in accordance with current clinical guidelines, expert recommendations, disease and patient characteristics, and patient needs/preferences.